363 related articles for article (PubMed ID: 16843266)
1. Activating alleles of JAK3 in acute megakaryoblastic leukemia.
Walters DK; Mercher T; Gu TL; O'Hare T; Tyner JW; Loriaux M; Goss VL; Lee KA; Eide CA; Wong MJ; Stoffregen EP; McGreevey L; Nardone J; Moore SA; Crispino J; Boggon TJ; Heinrich MC; Deininger MW; Polakiewicz RD; Gilliland DG; Druker BJ
Cancer Cell; 2006 Jul; 10(1):65-75. PubMed ID: 16843266
[TBL] [Abstract][Full Text] [Related]
2. JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model.
Mercher T; Wernig G; Moore SA; Levine RL; Gu TL; Fröhling S; Cullen D; Polakiewicz RD; Bernard OA; Boggon TJ; Lee BH; Gilliland DG
Blood; 2006 Oct; 108(8):2770-9. PubMed ID: 16804112
[TBL] [Abstract][Full Text] [Related]
3. Description of a novel Janus kinase 3 P132A mutation in acute megakaryoblastic leukemia and demonstration of previously reported Janus kinase 3 mutations in normal subjects.
Riera L; Lasorsa E; Bonello L; Sismondi F; Tondat F; Di Bello C; Di Celle PF; Chiarle R; Godio L; Pich A; Facchetti F; Ponzoni M; Marmont F; Zanon C; Bardelli A; Inghirami G
Leuk Lymphoma; 2011 Sep; 52(9):1742-50. PubMed ID: 21599579
[TBL] [Abstract][Full Text] [Related]
4. Functional analysis of JAK3 mutations in transient myeloproliferative disorder and acute megakaryoblastic leukaemia accompanying Down syndrome.
Sato T; Toki T; Kanezaki R; Xu G; Terui K; Kanegane H; Miura M; Adachi S; Migita M; Morinaga S; Nakano T; Endo M; Kojima S; Kiyoi H; Mano H; Ito E
Br J Haematol; 2008 May; 141(5):681-8. PubMed ID: 18397343
[TBL] [Abstract][Full Text] [Related]
5. Id1 is a common downstream target of oncogenic tyrosine kinases in leukemic cells.
Tam WF; Gu TL; Chen J; Lee BH; Bullinger L; Fröhling S; Wang A; Monti S; Golub TR; Gilliland DG
Blood; 2008 Sep; 112(5):1981-92. PubMed ID: 18559972
[TBL] [Abstract][Full Text] [Related]
6. Janus kinase 2: a critical target in chronic myelogenous leukemia.
Samanta AK; Lin H; Sun T; Kantarjian H; Arlinghaus RB
Cancer Res; 2006 Jul; 66(13):6468-72. PubMed ID: 16818614
[TBL] [Abstract][Full Text] [Related]
7. Loss-of-function JAK3 mutations in TMD and AMKL of Down syndrome.
De Vita S; Mulligan C; McElwaine S; Dagna-Bricarelli F; Spinelli M; Basso G; Nizetic D; Groet J
Br J Haematol; 2007 May; 137(4):337-41. PubMed ID: 17456055
[TBL] [Abstract][Full Text] [Related]
8. An activated receptor tyrosine kinase, TEL/PDGFbetaR, cooperates with AML1/ETO to induce acute myeloid leukemia in mice.
Grisolano JL; O'Neal J; Cain J; Tomasson MH
Proc Natl Acad Sci U S A; 2003 Aug; 100(16):9506-11. PubMed ID: 12881486
[TBL] [Abstract][Full Text] [Related]
9. A novel fusion of RBM6 to CSF1R in acute megakaryoblastic leukemia.
Gu TL; Mercher T; Tyner JW; Goss VL; Walters DK; Cornejo MG; Reeves C; Popova L; Lee K; Heinrich MC; Rush J; Daibata M; Miyoshi I; Gilliland DG; Druker BJ; Polakiewicz RD
Blood; 2007 Jul; 110(1):323-33. PubMed ID: 17360941
[TBL] [Abstract][Full Text] [Related]
10. Preclinical characterization of atiprimod, a novel JAK2 AND JAK3 inhibitor.
Quintás-Cardama A; Manshouri T; Estrov Z; Harris D; Zhang Y; Gaikwad A; Kantarjian HM; Verstovsek S
Invest New Drugs; 2011 Oct; 29(5):818-26. PubMed ID: 20372971
[TBL] [Abstract][Full Text] [Related]
11. Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing antileukemic agents.
Sudbeck EA; Liu XP; Narla RK; Mahajan S; Ghosh S; Mao C; Uckun FM
Clin Cancer Res; 1999 Jun; 5(6):1569-82. PubMed ID: 10389946
[TBL] [Abstract][Full Text] [Related]
12. Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells.
Yu C; Krystal G; Varticovksi L; McKinstry R; Rahmani M; Dent P; Grant S
Cancer Res; 2002 Jan; 62(1):188-99. PubMed ID: 11782377
[TBL] [Abstract][Full Text] [Related]
13. Targeting PIM kinases impairs survival of hematopoietic cells transformed by kinase inhibitor-sensitive and kinase inhibitor-resistant forms of Fms-like tyrosine kinase 3 and BCR/ABL.
Adam M; Pogacic V; Bendit M; Chappuis R; Nawijn MC; Duyster J; Fox CJ; Thompson CB; Cools J; Schwaller J
Cancer Res; 2006 Apr; 66(7):3828-35. PubMed ID: 16585210
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of the antigen-induced activation of rodent mast cells by putative Janus kinase 3 inhibitors WHI-P131 and WHI-P154 in a Janus kinase 3-independent manner.
Linwong W; Hirasawa N; Aoyama S; Hamada H; Saito T; Ohuchi K
Br J Pharmacol; 2005 Jul; 145(6):818-28. PubMed ID: 15852029
[TBL] [Abstract][Full Text] [Related]
15. Identification of mutant alleles of JAK3 in pediatric patients with acute lymphoblastic leukemia.
Yin C; Sandoval C; Baeg GH
Leuk Lymphoma; 2015 May; 56(5):1502-6. PubMed ID: 25146434
[TBL] [Abstract][Full Text] [Related]
16. Sole BCR-ABL inhibition is insufficient to eliminate all myeloproliferative disorder cell populations.
Wong S; McLaughlin J; Cheng D; Zhang C; Shokat KM; Witte ON
Proc Natl Acad Sci U S A; 2004 Dec; 101(50):17456-61. PubMed ID: 15505216
[TBL] [Abstract][Full Text] [Related]
17. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies.
Schittenhelm MM; Shiraga S; Schroeder A; Corbin AS; Griffith D; Lee FY; Bokemeyer C; Deininger MW; Druker BJ; Heinrich MC
Cancer Res; 2006 Jan; 66(1):473-81. PubMed ID: 16397263
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
Koch A; Scherr M; Breyer B; Mancini A; Kardinal C; Battmer K; Eder M; Tamura T
Oncogene; 2008 Aug; 27(34):4678-89. PubMed ID: 18427551
[TBL] [Abstract][Full Text] [Related]
19. JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma.
Bouchekioua A; Scourzic L; de Wever O; Zhang Y; Cervera P; Aline-Fardin A; Mercher T; Gaulard P; Nyga R; Jeziorowska D; Douay L; Vainchenker W; Louache F; Gespach C; Solary E; Coppo P
Leukemia; 2014 Feb; 28(2):338-48. PubMed ID: 23689514
[TBL] [Abstract][Full Text] [Related]
20. Activating mutations in human acute megakaryoblastic leukemia.
Malinge S; Ragu C; Della-Valle V; Pisani D; Constantinescu SN; Perez C; Villeval JL; Reinhardt D; Landman-Parker J; Michaux L; Dastugue N; Baruchel A; Vainchenker W; Bourquin JP; Penard-Lacronique V; Bernard OA
Blood; 2008 Nov; 112(10):4220-6. PubMed ID: 18755984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]